医药导报2024，Vol.43Issue(5)：769-773,5.DOI:10.3870/j.issn.1004-0781.2024.05.016
Toll样受体7激动剂治疗过敏性疾病的研究进展
Research Advances of Toll-like Receptor 7 Agonists in the Treatment of Allergic Diseases
摘要
Abstract
TLR7,a member of the Toll-like receptor family,is a type I transmembrane glycoprotein that consists of an external antigen recognition domain with 19-25 tandem leucine-rich repeat motifs and a cytoplasmic Toll/interleukin-1 receptor homology(TIR)signaling domain.TLR7 is mainly distributed in the inner membrane of plasma dendritic cells(pDC)and B cells in humans,and it shuttles from the endoplasmic reticulum to the endosome through the vesicles of the Golgi apparatus.TLR7 be-comes activated when it detects single-stranded RNA molecules from viruses,which triggers the production of type I interferon,the activation of TH1 cells,the rapid recruitment of inflammatory cells to the infected tissue,and the performance of antiviral,antitu-mor,and anti-allergic functions.There is a growing interest in using TLR7 agonists to treat allergic diseases,as its activation can control the ratio of TH1/TH2 cells.This article summarized preclinical research and clinical trials using TLR7 agonists for treating allergic rhinitis,allergic asthma,and allergic encephalitis,providing new viewpoints on the treatment of these diseases.关键词
TLR7 激动剂/Toll样受体/过敏性哮喘/过敏性鼻炎/过敏性脑炎Key words
TLR7 agonist/Toll-like receptors/Allergic asthma/Allergic Rhinitis/Allergic encephalitis分类
医药卫生引用本文复制引用
王玲,蔡铠红,詹文珠,殷国干,叶琳..Toll样受体7激动剂治疗过敏性疾病的研究进展[J].医药导报,2024,43(5):769-773,5.基金项目
国家自然科学基金面上项目(81870626、82371030) （81870626、82371030）
广东省高水平临床重点专科深圳市配套建设经费资助项目(SZGSP014). （SZGSP014）
